JUL 31, 2017 3:31 PM PDT

The Link Between BRCA Mutations and Prostate Cancer

WRITTEN BY: Xuan Pham

A study, published in the New England Journal of Medicine, examined DNA repair genes and whether mutations in these genes are highly prevalent in prostate cancer. They found that mutations in a gene commonly associated with breast cancer and ovarian cancer in women may also play a larger role in metastatic prostate cancer than doctors previously thought.

Image credit: Pixabay.com

The study results could mean a shift in how genetic testing is conducted for men with prostate cancer. In particular, men with the high-risk, metastatic form of the disease may want to be checked for heritable mutations that could be passed on to their children.

The team found that nearly 12 percent of the men were born with the DNA mutations associated with their cancer. This means a large proportion of these men inherited the DNA mutations from their parents. And in particular, mutations in the BRCA2 gene appeared in 5 percent of the men, making it the most commonly defective gene. Compared to men without prostate cancer, men with advanced prostate cancer were 18 times more likely to have a BRCA2 mutation.
 
The BRCA genes, also known as the Breast Cancer genes, are a well-known DNA repair genes in the context of breast and ovarian cancer. Mutations in this cancer duo account for 20 to 25 percent of all hereditary breast cancer types.


But while the perception of BRCA mutations has influenced the course of treatment for women at risk or battling breast cancer, the same mutations have yet to elicit a similar response for prostate cancer. And the research team hopes their study will change this.
 
"Our study has shown that a significant proportion of men with advanced prostate cancer are born with DNA repair mutations -- and this could have important implications for patients,” said Johann de Bono, professor at the ICR, who led the study in the United Kingdom. "Genetic testing for these mutations could identify men with advanced prostate cancer who may benefit from precision treatment. We could offer these men drugs such as PARP inhibitors, which are effective in patients with certain DNA repair mutations and are showing important anti-tumour activity in ongoing clinical trials.

Prostate cancer is the most common form of cancer in men, a statistic that highlights the need for better screening tools for this half of the population. "As doctors, we all know patients who say their father and grandfather had this cancer. We need to do trials to evaluate this risk. Then we could look at preventive strategies," said de Bono.
 
Though it’s too early to recommend screening in all men, the team hopes this will one day be a routine assessment. "In future testing all men with advanced disease for these mutations might help select the most effective treatments for them,” said Iain Frame, professor at the Prostate Cancer UK.
 


Additional source: Institute of Cancer ResearchBBC

About the Author
Bachelor's (BA/BS/Other)
I am a human geneticist, passionate about telling stories to make science more engaging and approachable. Find more of my writing at the Hopkins BioMedical Odyssey blog and at TheGeneTwist.com.
You May Also Like
OCT 11, 2022
Cell & Molecular Biology
Germ Cells Burrow Like Bulldozers
Germ Cells Burrow Like Bulldozers
In the early embryo, there is a cascade of cellular movement, and all of those cells have to move to the right position ...
OCT 13, 2022
Cancer
A Fungus Among Cancers
A Fungus Among Cancers
The cancer microbiome, the collection of microorganisms, including bacteria, viruses, and fungi, that live in or around ...
OCT 28, 2022
Cancer
Pancreatic Tumor Growth and Metastasis Inhibited
Pancreatic Tumor Growth and Metastasis Inhibited
Pancreatic ductal adenocarcinoma (PDAC), a highly aggressive type of pancreatic cancer, has a very poor prognosis due, a ...
NOV 28, 2022
Clinical & Molecular DX
Study Indicates that Breast Cancer Recurrence Could be Predicted Using a MicroRNA Biomarker
Study Indicates that Breast Cancer Recurrence Could be Predicted Using a MicroRNA Biomarker
MicroRNAs are small (between just 21 and 23 nucleotides), non-coding RNA molecules. They are involved in the post-transc ...
NOV 29, 2022
Cell & Molecular Biology
How a Master Regulator May be Working to Protect Cancer
How a Master Regulator May be Working to Protect Cancer
Scientists have now discovered yet another way that MYC proteins can promote cancer. MYC has been called a master regula ...
DEC 14, 2022
Genetics & Genomics
Labroots' Top 10 Scientific Discoveries of 2022
Labroots' Top 10 Scientific Discoveries of 2022
2022 was a big year for science, so let’s take a look at some of the most interesting -and important- scientific d ...
Loading Comments...